siltuximab

Home
Ligands
siltuximab

GtoPdb Ligand ID: 7396

Synonyms: cLLB8 | CNTO 328 | Sylvant®

siltuximab is an approved drug (EMA & FDA (2014))

Comment: Siltuximab is a monoclonal antibody targeting interleukin 6 (IL-6) [2].
Peptide sequences for the heavy and light chains of this antibody are annotated in its IMGT/mAb-DB record. The invention of siltuximab is covered by patent US7291721 [1].

References
1. Giles-Komar J, Knight D, Peritt D, Trikha M. (2007) Anti-IL-6 antibodies, compositions, methods and uses. Patent number: US7291721. Assignee: Centocor, Inc.. Priority date: 14/11/2001. Publication date: 06/11/2007.
2. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M et al.. (2010) Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol, 28 (23): 3701-8. [PMID:20625121]
3. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T et al.. (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood, 74 (4): 1360-7. [PMID:2788466]

References

1. Giles-Komar J, Knight D, Peritt D, Trikha M. (2007)
Anti-IL-6 antibodies, compositions, methods and uses.
Patent number: US7291721. Assignee: Centocor, Inc.. Priority date: 14/11/2001. Publication date: 06/11/2007.

2. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M et al.. (2010)
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
J Clin Oncol, 28 (23): 3701-8. [PMID:20625121]

3. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T et al.. (1989)
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.
Blood, 74 (4): 1360-7. [PMID:2788466]